icatibant / Generic mfg. - LARVOL DELTA

Isolated gastrointestinal hereditary angioedema associated with a pathogenic SERPING1 variant arising de novo: a case report. (PubMed, Front Med (Lausanne)) - "An abdominal attack in May 2025 resolved rapidly after icatibant administration. Long-term prophylaxis (LTP) with lanadelumab was subsequently initiated following an individualized shared decision-making process...This report highlights that HAE should be considered in patients with recurrent, unexplained, self-limiting abdominal pain, and C4 should be included in the initial evaluation. A negative family history does not exclude HAE."

Journal • Cardiovascular • Complement-mediated Rare Disorders • Gastrointestinal Disorder • Genetic Disorders • Hereditary Angioedema • Pain

Universal pipeline for high-resolution GPCR structure determination. (PubMed, Nat Struct Mol Biol) - "NOAH enabled structure determination of vasopressin V2 receptor bound to the antagonist tolvaptan or partial agonist OPC51803 and bradykinin B2 receptor bound to the antagonist icatibant, revealing receptor activation and inhibition mechanisms. Coupling NOAH to ARK1 improved the V2 receptor-tolvaptan map and enabled high-resolution structures of lysophosphatidic acid receptor 2 bound to Ki16425 and free fatty acid receptor 2 bound to GLPG0974. NOAH-ARK1 minimizes trial-and-error construct optimization and provides a broadly applicable route for GPCR structural analysis and drug discovery."

Journal • AURKA

On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation. (PubMed, Genes Dis) - No abstract available

Journal • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

Chronic Spontaneous Urticaria with Biochemical C1 Inhibitor Deficiency: A Case Report of Suspected Overlap with Hereditary Angioedema. (PubMed, Clin Cosmet Investig Dermatol) - "Documented treatment included H1 antihistamines, systemic corticosteroids, cyclosporine, and omalizumab. Subcutaneous icatibant and lanadelumab were also administered, but the retrospective records did not permit reliable assessment of icatibant response, and lanadelumab exposure was too brief to assess prophylactic efficacy...In patients with CSU, recurrent throat tightness or abdominal pain should prompt complement testing and episode-level assessment. Objective airway findings, abdominal evaluation, attack timing, complement results, and response to on-demand therapy should be documented before symptoms are attributed to a specific mechanism."

Journal • Cardiovascular • Chronic Spontaneous Urticaria • Complement-mediated Rare Disorders • Dermatology • Hereditary Angioedema • Immunology • Pain • Pruritus • Urticaria

Discovery of DAT-003 - a potent and selective small molecule antagonist of MRGPRX2 (ACS-Fall 2026) - "MRGPRX2 is a Mas-related G protein-coupled receptor expressed predominantly in mast cells that mediates IgE-independent degranulation in response to a wide range of endogenous and exogenous cationic ligands, including neuropeptides (substance P, VIP, cortistatin-14, PACAP1-38), eosinophil-derived proteins (MBP), and pharmacological agents such as icatibant...Finally, orally administered DA-003 also inhibited agonist-induced mast cell degranulation in the skin as measured by Evans blue vascular permeability assay in human MRGPRX2 knock-in mice. These data establish DA-003 as a potent, selective, and mechanistically clean MRGPRX2 antagonist with the potential to address the non-IgE component of mast cell-driven inflammatory disease."

Chronic Spontaneous Urticaria • Immunology • Inflammation • Urticaria • CD34 • CORT • CXCL8 • IL5

Real-World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (HAE): Post-Marketing Surveillance in Japan. (PubMed, J Dermatol) - P | "In conclusion, in this study of the real-world use of icatibant, no new safety concerns were reported. Icatibant was effective in providing early symptom relief for HAE attacks across a broad spectrum of patients, including patients with HAE-nC1INH, who were not included in previous clinical trials."

Journal • P4 data • Real-world evidence • Cardiovascular • Complement-mediated Rare Disorders • Gastrointestinal Disorder • Hereditary Angioedema • Immunology

Delayed Airway Catastrophe in ACE-Inhibitor-Induced Angioedema Despite ICU Monitoring (ASA 2026) - "A 46-year-old male on chronic lisinopril presented with recurrent lingual angioedema without initial respiratory distress. Despite treatment with corticosteroids, antihistamines, tranexamic acid, and icatibant, he had persistent severe swelling with Mallampati IV airway, voice changes, and secretion intolerance requiring ICU monitoring...Return of spontaneous circulation was achieved after prolonged resuscitation. This case highlights the risk of delayed airway compromise in ACE inhibitor-induced angioedema despite close observation."

Cardiovascular • Pulmonary Disease

Pediatric hereditary angioedema presenting as recurrent episodic abdominal pain and vomiting: Challenges in diagnosis and management. (PubMed, JPGN Rep) - "We present the challenging diagnostic odyssey of a pediatric patient (symptom onset at age 4 years; diagnosis at age 8), culminating in an unexpected diagnosis of hereditary angioedema, a critical etiology often omitted from differentials. This case underscores a key gap in current clinical pathways and serves to expand the diagnostic consideration for specialists managing unexplained recurrent episodic abdominal symptoms."

Journal • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema • Pain • Pediatrics

Current and future therapies for bradykinin-mediated angioedema (PubMed, Dermatologie (Heidelb)) - "On-demand treatment options include plasma-derived and recombinant C1 inhibitor (C1INH) concentrates, the bradykinin B2 receptor antagonist icatibant, and, more recently, the first orally available plasma kallikrein inhibitor, sebetralstat...LTP therapies include subcutaneous and intravenous C1INH preparations, the oral kallikrein inhibitor berotralstat, the anti-kallikrein monoclonal antibody lanadelumab, the factor XIIa inhibitor garadacimab, and the antisense oligonucleotide donidalorsen. Currently under development are the oral bradykinin B2 receptor antagonist deucrictibant, which is intended for both on-demand treatment and long-term prophylaxis in different formulations, long-acting antibodies, such as navenibart, and CRISPR/Cas9-based gene-editing therapies, such as NTLA-2002 with potential functional curative properties. In particular, orally available and long-acting therapies are expected to improve adherence, self-management, and quality of life in..."

Journal • Review • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

Pharmacological Characterization of Vasomotor Responses in the Tree Shrew (Tupaia belangeri) Basilar Artery: A Promising Model for Human Cerebrovascular Research. (PubMed, Biology (Basel)) - "BK-induced relaxation was inhibited by the B2 antagonist HOE140 and Nω-nitro-L-arginine (L-NA), but not by B1 antagonists or indomethacin, suggesting a B2 receptor-mediated nitric oxide (NO) pathway. These findings demonstrate that 5-HT1/5-HT2 and H1 receptors mediate contraction, while B2 and M3 receptors mediate relaxation in the tupaia basilar artery. This study highlights species-specific cerebrovascular regulation and supports the tupaia as a relevant model for investigating human cerebrovascular physiology and pathophysiology."

Journal

Bradykinin B2 Receptor Triggers ITPR1-Mediated ER Calcium Release in Trigeminal Ganglion Neurons to Drive Trigeminal Neuropathic Pain. (PubMed, Mol Pain) - "Following peripheral nerve injury, the B2 receptor-ITPR1 signaling mediated ER calcium release represents an essential mechanism underlying the development and maintenance of trigeminal neuropathic pain. Targeting this signaling pathway effectively attenuates peripheral neuronal hyperexcitability, providing novel experimental evidence and potential therapeutic targets for the management of trigeminal neuralgia."

Journal • Neuralgia • Pain

Angioedema due to acquired C1-inhibitor deficiency: a systematic literature review (ISTH 2026) - "Among patients with hematological disorders, 51 received a rituximab-based therapy...On-demand treatment for acute attacks was reported on in 109 patients, most frequently icatibant (45.0%) or C1INH-concentrate (43.1%)...Table or Figure Upload (1) Figure 1. PRISMA flow diagram for identification of studies via databases Page 2 DOI*10.1016/j.rpth.2026.105775"

Review • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Hereditary Angioedema • Lymphoma • Marginal Zone Lymphoma • Monoclonal Gammopathy • Rare Diseases

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema (clinicaltrials.gov) - P=N/A | N=32 | Completed | Sponsor: Takeda | Trial completion date: Oct 2025 ➔ May 2026 | Trial primary completion date: Oct 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema • Pediatrics

Overactivated bradykinin-B2 receptor promotes type a aortic dissection by inducing endothelial dysfunction: Therapeutic effect of icatibant. (PubMed, Life Sci) - "Our findings demonstrate that BK-driven B2R activation induces endothelial dysfunction and TAAD. Targeting this pathway with icatibant mitigates disease progression, nominating B2R inhibition as a viable pharmacological strategy against TAAD."

Journal • Cardiovascular

Living-Donor Kidney Transplantation Between Mother and Son With Clinically Confirmed Hereditary Angioedema. (PubMed, Pediatr Transplant) - "This report demonstrates that living-donor kidney transplantation between two individuals affected by HAE can be performed safely with individualized prophylaxis and multidisciplinary coordination."

Journal • Cardiovascular • Chronic Kidney Disease • Complement-mediated Rare Disorders • Hereditary Angioedema • Nephrology • Renal Calculi • Transplantation

Isolated angioedema in the emergency department: rarely an allergic reaction. (PubMed, Am J Emerg Med) - "Differentiating between these pathways is critical, as standard anaphylaxis treatments like epinephrine are often ineffective for non-allergic variants...Effective treatment requires a targeted approach based on the underlying mechanism, including antihistamines for histamine-mediated reactions and on-demand therapies for bradykinin-mediated hereditary angioedema, such as C1-esterase inhibitor concentrate, icatibant, and the recently approved oral kallikrein inhibitor sebetralstat. This article provides a clinical framework to help emergency physicians identify the correct underlying mechanism. Ultimately, accurate diagnosis facilitates appropriate specialist referral and improves long-term patient outcomes."

Journal • Review • Allergy • Cardiovascular • Chronic Spontaneous Urticaria • Complement-mediated Rare Disorders • Dermatology • Hereditary Angioedema • Immunology • Urticaria

Bradykinin B2 Receptor Antagonist Icatibant As A Novel Drug For The Management Of Vascular Dementia. (AAIC 2026) - No abstract available

Alzheimer's Disease • CNS Disorders • Dementia

Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review. (PubMed, Allergy Asthma Proc) - " Icatibant was safe and effective in the pediatric studies, providing rapid symptoms relief and a favorable tolerability profile. Despite limitations from small sample sizes and lack of comparator trials, current evidence supports icatibant as a targeted, practical option for treating acute HAE attacks in children."

Journal • Review • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema • Pain • Pediatrics

Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks. (PubMed, Adv Ther) - "Substantial heterogeneity in trial design, attack eligibility criteria, redosing and rescue protocols, censoring rules, and endpoint definitions limit cross-trial comparability of on-demand HAE therapies. Future comparative efficacy research should prioritize harmonization of endpoint definitions, map across PRO instruments, and adjust for treatment effect modifiers."

Clinical • Journal • Review • Cardiovascular • Complement-mediated Rare Disorders • Genetic Disorders • Hereditary Angioedema

Characterization of hereditary angioedema population in Argentina: A nationwide study. (PubMed, World Allergy Organ J) - "Icatibant was the most prescribed drug (76.91%). Long-term prophylaxis (LTP) was used in 28.34% of subjects, with lanadelumab being the most prescribed agent (58.45%). Argentine HAE patients share several characteristics with patients from real-world studies, but some findings (time to diagnosis, low LTP rates, relatively high rates of HAE-FXII and a novel, recently characterized form of HAE-DAB2IP) require further research."

Journal • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema • DAB2IP

Recurrent abdominal attacks as a presentation of hereditary angioedema type I: a multigenerational family series. (PubMed, Rev Esp Enferm Dig) - "After diagnosis, the index case received on-demand icatibant and initiated long-term prophylaxis with lanadelumab, remaining asymptomatic at the most recent follow-up. This series highlights the importance of considering HAE in patients with unexplained recurrent abdominal pain, edema without urticaria, and a suggestive family history, particularly when imaging suggests reversible small-bowel involvement, in order to reduce diagnostic delay and prevent potentially avoidable interventions."

Journal • Cardiovascular • Complement-mediated Rare Disorders • Dermatology • Hereditary Angioedema • Immunology • Pain • Urticaria

Could bradykinin pathway inhibition change the course of severe hantavirus disease? (PubMed, Immunol Lett) - "This translational mechanism is tentatively supported by two clinical case reports where severe hantavirus infections were successfully treated with the bradykinin receptor antagonist icatibant. We hypothesize that exaggerated bradykinin signalling drives the vascular leak phenotype, making the kallikrein-kinin pathway a compelling therapeutic target. Ultimately, effectively combating hantavirus-induced vascular permeability may require a multi-faceted approach combining targeted bradykinin inhibition with broader immunomodulatory strategies."

Journal • Infectious Disease • Inflammation

First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib. (PubMed, Clin Microbiol Infect) - "This sentinel case of imported HCPS in non-endemic Europe was managed with, to our knowledge, the first reported combined antiviral and host-directed regimen for this syndrome and the first reported use of favipiravir in a patient with hantavirus infection. The favourable outcome supports prospective evaluation of antiviral combinations and adjunctive immunomodulation within international preparedness protocols."

Journal • Hematological Disorders • Immunology • Infectious Disease • Respiratory Diseases • Thrombocytopenia

AB102 is a potent and orally bioavailable small molecule inhibitor of MRGPRX2 (SID 2026) - "In vivo efficacy was assessed in human-MRGPRX2 knock-in (KI) mice via acute paw swelling (substance P or icatibant induced wheal-and-flare), systemic anaphylaxis (ciprofloxacin), and chronic calcipotriol (MC903)-induced AD-like models. In chronic inflammation, AB102 markedly attenuated MC903-driven ear swelling, transepithelial water loss, and epidermal/dermal thickening, while reducing IL-13 and TSLP transcripts. AB102 is a highly selective MRGPRX2 antagonist that effectively suppresses both acute and chronic mast cell–driven inflammation, supporting its potential as an oral therapeutic for mast cell-mediated disorders."

Atopic Dermatitis • Chronic Spontaneous Urticaria • Dermatitis • Immunology • Inflammation • Urticaria • IL13 • TSLP

ON-DEMAND TREATMENTS FOR HEREDITARY ANGIOEDEMA AND HEALTHCARE RESOURCE UTILIZATION IN PEDIATRIC (2-11 YEARS) PATIENTS: A US CLAIMS DATABASE ANALYSIS (ISPOR 2026) - "A standardized dose was defined as one icatibant syringe, one rhC1INH vial, three ecallantide vials, or two pdC1INH (Berinert) vials. On-demand treatment options are limited for the US pediatric HAE population with only IV pdC1INH being FDA-approved. This analysis found that most (62%) pediatric patients had claims of pdC1INH, which contributed 40% of total on-demand doses. This contrasts with icatibant where 24% of patients contributed to the same total on-demand dose share."

Claims database • Clinical • HEOR • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema • Pediatrics